Tirzepatide vs. Semaglutide: Which GLP-1 Drug Should You Choose for Weight Loss? | Research

The takeaway

Tirzepatide produces more weight loss while semaglutide has stronger cardiovascular protection data — the best choice depends on the individual patient's priorities.

Different strengths
Tirzepatide yields greater weight loss and broader metabolic benefits; semaglutide offers proven cardiovascular protection from the SELECT trial — choice depends on patient priorities

What the researchers found

Semaglutide and tirzepatide represent two complementary but distinct approaches to obesity pharmacotherapy. Tirzepatide (dual GIP/GLP-1 agonist) produces greater weight loss and broader metabolic benefits, while semaglutide (GLP-1 agonist) has demonstrated robust cardiovascular protection with dedicated outcomes data from the SELECT trial.

The review synthesizes data from the major clinical trial programs: STEP and SELECT for semaglutide, SURMOUNT and SUMMIT for tirzepatide. It frames the choice between the two drugs as a clinical decision that depends on the individual patient's priorities — maximum weight loss and metabolic improvement (favoring tirzepatide) versus proven cardiovascular risk reduction (favoring semaglutide). Both drugs require clinicians to treat obesity as a chronic disease needing ongoing pharmacological management rather than a lifestyle issue with a temporary fix.

Why it matters

This is the most common clinical question in obesity medicine today: which drug should I choose? By synthesizing the major trial data side by side, this review helps clinicians make evidence-based decisions. The key insight — that the two drugs have different strengths — means the choice isn't simply about which is 'better' but about matching the drug to the patient's specific clinical needs.

The numbers in context

STEP trials (semaglutide) · SELECT trial (cardiovascular outcomes) · SURMOUNT trials (tirzepatide) · SUMMIT trial (heart failure) · Tirzepatide: greater weight loss · Semaglutide: proven CV protection · 2020-2025 literature

How the study worked

Comparative review synthesizing data from pivotal clinical trials (STEP, SELECT, SURMOUNT, SUMMIT) for semaglutide and tirzepatide. Literature search conducted via PubMed and Google Scholar plus major cardiology and endocrinology publications from 2020 to 2025. Published in Expert Opinion on Pharmacotherapy.

Who was studied

Adults with obesity (with and without type 2 diabetes, cardiovascular disease, and heart failure)

What this study cannot tell us

No head-to-head RCT directly comparing semaglutide and tirzepatide exists, so comparisons are indirect across different trial populations. The review reflects data available through early 2025; newer trial readouts may shift the balance. Narrative format rather than systematic review. Access, cost, and insurance coverage considerations are discussed but may vary significantly by region.

How to read the evidence

Published in Expert Opinion on Pharmacotherapy by leading obesity researchers including Carel le Roux. The review synthesizes data from major phase III programs (STEP, SELECT, SURMOUNT, SUMMIT), representing the strongest available clinical evidence. However, cross-trial comparisons are inherently indirect.

When this study was published

Published in 2025 with literature through 2025. Highly current and directly relevant to ongoing clinical decision-making between these two drugs.

The bigger picture

The emergence of two distinct but highly effective peptide-based obesity drugs marks a turning point in medicine. For the first time, clinicians can make personalized choices between obesity medications based on individual patient profiles — similar to how different statins or blood pressure medications are selected. This review reflects the maturation of the GLP-1 field from a single-drug paradigm to a pharmacological toolkit.

Questions still open

Will a head-to-head RCT directly comparing semaglutide and tirzepatide ever be conducted?
Will tirzepatide's cardiovascular outcomes data (from SUMMIT and upcoming trials) match semaglutide's SELECT results?
As triple agonists like retatrutide enter the market, how will the decision framework expand beyond two drugs?

Common questions

Which is better for weight loss: semaglutide or tirzepatide?

Tirzepatide generally produces greater weight loss than semaglutide based on their respective clinical trial programs. However, semaglutide has dedicated cardiovascular outcomes data (the SELECT trial) showing it reduces heart attacks and strokes. The best choice depends on whether maximum weight loss or cardiovascular protection is the higher priority for a given patient.

Do you have to take these drugs forever?

This review emphasizes that obesity is a chronic disease requiring ongoing management. Clinical trial data shows that weight tends to return after stopping either drug. The authors argue that clinicians should reconceptualize obesity pharmacotherapy as long-term treatment, similar to medications for high blood pressure or cholesterol.

Read the original research

Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.

Expert opinion on pharmacotherapy, 26(17), 1841-1854

View on PubMed ↗Publisher’s paper ↗

Citation

Mondoh, Alvin; Crotty, Michael; le Roux, Carel W. (2025). Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape.. Expert opinion on pharmacotherapy, 26(17), 1841-1854. https://doi.org/10.1080/14656566.2025.2601060